BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38361033)

  • 1. Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression.
    Hu J; Wang SG; Hou Y; Chen Z; Liu L; Li R; Li N; Zhou L; Yang Y; Wang L; Wang L; Yang X; Lei Y; Deng C; Li Y; Deng Z; Ding Y; Kuang Y; Yao Z; Xun Y; Li F; Li H; Hu J; Liu Z; Wang T; Hao Y; Jiao X; Guan W; Tao Z; Ren S; Chen K
    Nat Genet; 2024 Mar; 56(3):442-457. PubMed ID: 38361033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Multi-omic Profiling of Clear Cell Renal Cell Carcinoma Identifies Metabolic Reprogramming Associated with Disease Progression.
    Jiang A; Qu L; Cai C; Luo P; Wang L
    Eur Urol; 2024 Jul; 86(1):76-77. PubMed ID: 38614822
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.
    Liu Y; Qi L; Ye B; Wang A; Lu J; Qu L; Luo P; Wang L; Jiang A
    Cancer Biol Ther; 2024 Dec; 25(1):2345977. PubMed ID: 38659199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
    Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
    BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.
    Wang Y; Chen L; Wang G; Cheng S; Qian K; Liu X; Wu CL; Xiao Y; Wang X
    J Cell Physiol; 2019 Jul; 234(7):10225-10237. PubMed ID: 30417363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
    Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
    J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma.
    Neely BA; Wilkins CE; Marlow LA; Malyarenko D; Kim Y; Ignatchenko A; Sasinowska H; Sasinowski M; Nyalwidhe JO; Kislinger T; Copland JA; Drake RR
    PLoS One; 2016; 11(4):e0154074. PubMed ID: 27128972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
    Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
    Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
    Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
    World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma.
    Yang Y; Liang J; Zhao J; Wang X; Feng D; Xu H; Shen Y; Zhang Y; Dai J; Wang Z; Wei Q; Liu Z
    Diagn Pathol; 2023 Aug; 18(1):96. PubMed ID: 37608295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.
    Tanaka K; Kandori S; Sakka S; Nitta S; Tanuma K; Shiga M; Nagumo Y; Negoro H; Kojima T; Mathis BJ; Shimazui T; Watanabe M; Sato TA; Miyamoto T; Matsuzaka T; Shimano H; Nishiyama H
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34841437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of
    Wang T; Xie F; Li YH; Liang B
    Future Oncol; 2021 Dec; 17(36):5033-5044. PubMed ID: 34704468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma.
    Li Z; Chen Y; Hu S; Zhang J; Wu J; Ren W; Shao N; Ying X
    Oncotarget; 2016 Dec; 7(50):82671-82685. PubMed ID: 27705920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
    Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
    Front Immunol; 2022; 13():861328. PubMed ID: 35479084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.